Investor Presentaiton

7 Investor presentation Full year 2022 Novo NordiskⓇ International Operations diabetes care sales growth is driven by GLP-1 performance Reported Diabetes care sales and growth per IO geography DKK billion 75 60 60 10% GLP-1 patients and value market share in IO Insulin I GLP-1 Growth at CER Number of patients (millions) Value market share Class growth >50% 5 75% 64.0% 4 Geographical regions 60% 57% 45 45 3 13% 2 30 1 43% 26% -7% -9% 15 78% 1 88% -3% -22% 5% 0 0 IO EMEA China ROW Nov-20 Nov-21 42.8% 45% 33.9% 30% 14.4% 15% 6.7% 0% Nov-22 -OzempicⓇ ―dulaglutide Source: IQVIA MAT, Nov 2022 (Spot rate). Note that the market share and patient numbers are based on countries with IQVIA coverage. GLP-1 class growth calculated as Sep-Nov 2022 vs Sep-Nov 2021 (Rolling 3 month average) IO: International Operations; NN: Novo Nordisk; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; ROW: Rest of World; R3M: Rolling three months -VictozaⓇ -NN GLP-1 GLP-1 patients Ⓡ ▪Rybelsus

View entire presentation